生长激素分泌型垂体腺瘤所致肢端肥大症的管理:神经外科医生手术与多模式管理策略的实用综述
本综述汇总已发表研究,介绍生长激素分泌型垂体腺瘤(GHPA)所致肢端肥大症的病史、诊断标准、术前预后因素、手术及多模式辅助治疗。手术可使超过三分之二的患者治愈,作者团队及其他中心近期激素缓解率约为70%-80%,少数未单靠手术缓解者加用药物治疗后升至85%以上。神经外科医生在其中起主要且常为决定性的作用,多学科团队协作可优化生化治愈机会。
要点
- 手术可使超过三分之二的肢端肥大症患者治愈,近期激素缓解率约70%-80%。
- 少数单靠手术未缓解者加用药物治疗后缓解率升至85%以上。
- 术前生长激素水平、海绵窦侵犯和腺瘤质地是决定切除范围的重要因素。
核心结论
- 神经外科医生在肢端肥大症管理中起主要且常为决定性的作用,多学科团队协作可优化生化治愈机会,即使对大而侵袭性的GHPA也是如此。
研究设计与样本
- 本综述汇总并回顾已发表研究,其中许多由擅长垂体腺瘤管理的颅底神经外科医生、内分泌科医生和放射肿瘤科医生撰写。
主要发现
- 手术可使超过三分之二的肢端肥大症患者治愈。
- 作者团队及其他中心近期切除GHPA后的激素缓解率约为70%-80%,少数单靠手术未缓解者加用药物治疗后升至85%以上。
- 多数肿瘤可经直接内镜下经鼻蝶入路到达,必要时可联合各种扩大入路进入鞍上、斜坡和鞍旁区域。
- 术前生长激素水平、海绵窦侵犯和垂体腺瘤质地是决定切除范围的重要因素。
- 多数残留或复发患者的药物治疗(如生长抑素类似物和多巴胺激动剂)可帮助实现激素缓解;必要时多数病例可安全再次手术,立体定向放射外科通常保留用于药物抵抗且位于手术难以到达区域的肿瘤。
临床怎么用
- 多数肿瘤可经直接内镜下经鼻蝶入路切除,必要时联合扩大入路进入鞍上、斜坡和鞍旁区域。
- 多数残留或复发患者可使用药物治疗(如生长抑素类似物和多巴胺激动剂)帮助实现激素缓解。
- 必要时多数病例可安全再次手术,立体定向放射外科通常保留用于药物抵抗且位于手术难以到达区域的肿瘤。
- 神经外科、耳鼻喉科、内分泌科和放射肿瘤科专家组成的整合多学科团队参与可优化生化治愈机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review aimed to highlight the history, diagnostic criteria, preoperative prognostic factors, surgical management, and multimodal adjuvant therapies recommended to provide a comprehensive and multifaceted understanding of and clinical approach to treating growth hormone-secreting pituitary adenomas (GHPAs) in patients with acromegaly. The authors collated and reviewed published studies, many written by skull base neurosurgeons, endocrinologists, and radiation oncologists with expertise in pituitary adenoma management, to produce a practical and contemporary update pertaining to the optimal management of acromegaly for neurosurgeons. Acromegaly is a debilitating disease for which surgery can be curative in more than two-thirds of patients. Recent rates of hormonal remission by the authors' group and others following the resection of GHPAs are on the order of 70%-80%, and these increase to more than 85% with the addition of medical therapy in a minority of patients who do not achieve remission with surgery alone. Most tumors are accessible via a direct endoscopic endonasal transsphenoidal approach, which can be augmented with a variety of extended approaches to gain access to suprasellar, clival, and parasellar compartments as needed. Preoperative growth hormone levels, cavernous sinus invasion, and pituitary adenoma consistency are important factors in determining the extent of resection. In most patients with residual or recurrent disease, medical therapy (e.g., somatostatin analogs and dopamine agonists) can be used to help achieve hormonal remission. Repeat surgery can be safely performed in most cases if needed, whereas stereotactic radiosurgery is usually reserved for medically resistant tumors in surgically inaccessible compartments. The neurosurgeon has a primary and often definitive role in the management of acromegaly. The involvement of an integrated and multidisciplinary team consisting of experts from neurosurgery, otolaryngology, endocrinology, and radiation oncology optimizes the chances for a biochemical cure, even in large and aggressive GHPAs.
引用
- Cheok SK, Carmichael JD, Zada G, et al. Management of growth hormone-secreting pituitary adenomas causing acromegaly: a practical review of surgical and multimodal management strategies for neurosurgeons. J Neurosurg. 2023. PMID: 37948697. doi:10.3171/2023.8.JNS221975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。